LONDON, UK, 21 February 2022 – Theragnostics announces that NephroScan, its radiodiagnostic imaging drug used as an aid for the evaluation of renal parenchymal disorders in adult and pediatric patients, including term neonates, has received…Original Article
FDA Approves NephroScan (Kit for the Preparation of Technetium Tc 99m Succimer Injection) for Radiodiagnostic Imaging
